Rodzajewska A, Kuryło W, Szklener K. Impressive clinical response following combined BRAF and MEK inhibition in a low-grade serous ovarian carcinoma patient with a BRAF V600E mutation. J Educ Health Sport [Internet]. 2023 Aug. 8 [cited 2024 Nov. 27];31(1):138-47. Available from: https://apcz.umk.pl/JEHS/article/view/44940